TPI1 and neoplasm: To validate the LAIR1 downstream effector molecule SHP-1 as a therapeutic target, 344SQ tumors were treated with the SHP-1 inhibitor, TPI-1, which was sufficient as a single-agent to reduce primary tumor growth (Fig. 6a, Supplementary Fig. 10d).